SCHEMBL24082020

SCHEMBL24082020

CCOC(=O)C(=O)C(CCCC(=O)OC)C(=O)OC

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.37
CYP1A2 P05177 1/20 0.37
KMT2A Q03164 2/20 0.36
POLB P06746 1/20 0.36
GAA P10253 2/20 0.35
MGAM O43451 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
ALDH1A1 P00352 2/20 0.34
LMNA P02545 1/20 0.34
MAPK1 P28482 2/20 0.34
HPGD P15428 1/20 0.34
ZDHHC7 Q9NXF8 1/20 0.33
MAPT P10636 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24082211 0.95 TSHR (0.42) TSHRL3MBTL1CYP1A2KMT2APOLB
SCHEMBL25224860 0.90 TSHR (0.40) TSHRL3MBTL1CYP1A2KMT2APOLB
SCHEMBL6885929 0.85 TSHR (0.48) TSHRL3MBTL1CYP1A2KMT2APOLB
SCHEMBL15987047 0.83 CYP1A2 (0.47) TSHRL3MBTL1CYP1A2KMT2APOLB
SCHEMBL11592937 0.82 TSHR (0.58) TSHRL3MBTL1KMT2ACA1CA2
SCHEMBL24082217 0.82 TSHR (0.45) TSHRL3MBTL1CYP1A2KMT2APOLB
SCHEMBL22631505 0.81 TSHR (0.52) TSHRL3MBTL1CYP1A2KMT2APOLB
SCHEMBL24081981 0.79 ALDH1A1 (0.38) L3MBTL1KMT2APOLBGAAMGAM
SCHEMBL11598804 0.77 TSHR (0.56) TSHRL3MBTL1KMT2ACA1CA2
SCHEMBL7518295 0.77 GAA (0.39) TSHRPOLBGAAMGAMSI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12331038-B2 Hexone glucokinase inhibitor and use thereof SHANDONG XUANZHU PHARMA CO., LTD. (CN) 2025-06-17 US disclosed
EP-3919484-B1 HEXONE GLUCOKINASE INHIBITOR AND USE THEREOF SHANDONG XUANZHU PHARMA CO LTD (CN) 2023-05-24 EP disclosed
US-20220106299-A1 HEXONE GLUCOKINASE INHIBITOR AND USE THEREOF SHANDONG XUANZHU PHARMA CO., LTD. (CN) 2022-04-07 US disclosed
EP-3919484-A1 HEXONE GLUCOKINASE INHIBITOR AND USE THEREOF Shandong Xuanzhu Pharma Co., Ltd. (CN) 2021-12-08 EP disclosed
EP-3919484-A1 HEXONE GLUCOKINASE INHIBITOR AND USE THEREOF Shandong Xuanzhu Pharma Co., Ltd. (CN) 2021-12-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12331038-B2 Hexone glucokinase inhibitor and use thereof GCK, KHK, HK1 TSHR 4107/4885L3MBTL1 4124/4885CYP1A2 1259/4885
US-20220106299-A1 HEXONE GLUCOKINASE INHIBITOR AND USE THEREOF GCK, KHK, HK1 TSHR 4107/4885L3MBTL1 4124/4885CYP1A2 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.